Novo Nordisk A/S (Novo Nordisk A/S) Sloan Ratio % : 5.99% (As of Dec. 2023)

Novo Nordisk A/S Sloan Ratio % Chart

Novo Nordisk A/S Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Sloan Ratio %		Get a 7-Day Free Trial					2.93	8.71	12.52	0.64	5.94

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sloan Ratio %	Get a 7-Day Free Trial															0.66	2.37	4.37	3.92	5.99

Competitive Comparison of Novo Nordisk A/S's Sloan Ratio %

For the Biotechnology subindustry, Novo Nordisk A/S's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Sloan Ratio % falls into.

Novo Nordisk A/S Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Novo Nordisk A/S's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Novo Nordisk A/S's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Novo Nordisk A/S's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 2850.033 (Mar. 2023 ) + 2827.166 (Jun. 2023 ) + 3216.795 (Sep. 2023 ) + 3213.408 (Dec. 2023 ) = $12,107 Mil.
Novo Nordisk A/S's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 4288.427 (Mar. 2023 ) + 4158.53 (Jun. 2023 ) + 5862.587 (Sep. 2023 ) + 1397.407 (Dec. 2023 ) = $15,707 Mil.
Novo Nordisk A/S's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -956.1 (Mar. 2023 ) + -1351.155 (Jun. 2023 ) + -1895.187 (Sep. 2023 ) + -2153.245 (Dec. 2023 ) = $-6,356 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S  (NYSE:NVO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Novo Nordisk A/S has a Sloan Ratio of 5.99%, indicating the company is in the safe zone and there is no funny business with accruals.

Novo Nordisk A/S Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description